AI assistant
IDEXX LABORATORIES INC /DE — Director's Dealing 2020
May 20, 2020
30016_dirs_2020-05-20_c99ef548-8184-47de-9e09-2b6428bff945.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2020-05-19
Reporting Person: JUNIUS DANIEL M (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-05-19 | Common Stock | M | 4000 | $63.95 | Acquired | 6834 | Direct |
| 2020-05-19 | Common Stock | S | 4000 | $295.6082 | Acquired | 2834 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-05-19 | Non-Qualified Stock Option (right-to-buy) | $63.95 | M | 4000 | Disposed | 2025-05-05 | Common Stock (4000) | Direct |
Footnotes
F1: Represents the weighted average price of the shares sold ranging from a low of $295.68 to a high of $295.735 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F2: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 3,861 shares on May 6, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F3: Not applicable.